 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
16 News |  |
- alofanib (RPT835) - R / Pharm, OM-RCA-01 / OncoMax, Yervoy (ipilimumab) / Ono Pharma, BMS
Overcoming resistance to immunotherapy with FGFR inhibition in GU cancer models () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2606;
OM-RCA-01, a anti-FGFR1 humanized antibody, and alofanib, a FGFR2 allosteric inhibitor showed promising results in previous studies...Treatment with ipilimumab (ipi, 200 mcl on days 7, 10, and 13) was initiated in both cohorts when tumor volumes reached 70 mm3...The table summarizes the results of in vivo studies. Table: 1073P Conclusions Inhibition of FGFR1 and FGFR2 following immunotherapy resulted in a twofold suppression of tumor growth, especially in the CAFs+ cohort.
- || alofanib (RPT835) - R / Pharm
P1 data, Clinical Trial,Phase I, Journal, Metastases: A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer. (Pubmed Central) - May 1, 2023
P1b
Alofanib showed acceptable tolerability and preliminary signs of clinical activity in the late-line treatment of metastatic gastric cancer. (ClinicalTrials.gov identifier: NCT04071184).
- alofanib (RPT835) / Russian Pharmaceutical Technologies
Alofanib in subsequent therapy for advanced gastric cancer: Final results from the phase Ib clinical trial. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2162;
P1b
Alofanib was feasible and showed early signals of efficacy in heavily-pretreated patients with metastatic gastric cancer. A phase 2 randomized trial is planned.
- alofanib (RPT835) / Russian Pharmaceutical Technologies
Pharmacokinetics of alofanib and biomarker analysis in patients with advanced gastric cancer: A phase 1b study (Section 34) - Mar 9, 2022 - Abstract #AACR2022AACR_5216;
FGFR2 amplification was confirmed by FISH in 1 (5.6%) patient.Alofanib PK in a gastric patient population is well characterized, supporting the use of a once-daily 350 mg/m2 dose. In further studies, the evaluation of FGFR2 amplification seems to be important.
- alofanib (RPT835) / Russian Pharmaceutical Technologies
Alofanib in subsequent therapy of advanced gastric cancer: Final results from the phase Ib clinical trial ([VIRTUAL]) - Mar 4, 2022 - Abstract #ESMOTAT2022ESMO_TAT_148;
P1b
In further studies, the evaluation of FGFR2 amplification seems to be important. Alofanib was feasible and showed early signals of efficacy in heavily-pretreated patients with metastatic gastric cancer.
- alofanib (RPT835) / Russian Pharmaceutical Technologies
A first-in-human phase 1b study of a novel allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer. (Live Stream | Level 1, West Hall; Poster Board - F8) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_93;
P1b
The MTD has not been reached and dose of 350 mg/m2 has been declared as RP2D. Alofanib showed acceptable tolerability and preliminary signs of clinical activity in the late-line treatment of metastatic gastric cancer.
- alofanib (RPT835) / Russian Pharmaceutical Technologies
[VIRTUAL] Preliminary data on a phase 1b, first-in-human study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer () - Mar 11, 2021 - Abstract #AACR2021AACR_2557;
P1b
The early biologic activity of alofanib in the late-line treatment of metastatic gastric cancer is encouraging. In addition to the above, any updated safety, PK, and efficacy data will be presented at the time of the AACR meeting.
- alofanib (RPT835) / Russian Pharmaceutical Technologies
[VIRTUAL] Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: a phase 1b study in patients with advanced gastric cancer (RPT835GC1B) () - Feb 8, 2021 - Abstract #TAT2021TAT_140;
P1b
PK profiles did not correlate with toxicity and efficacy of alofanib. The study is ongoing.
- alofanib (RPT835) / Russian Pharmaceutical Technologies
[VIRTUAL] Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: a phase 1b study in patients with advanced gastric cancer (RPT835GC1B) () - Feb 8, 2021 - Abstract #TAT2021TAT_36;
P1b
PK profiles did not correlate with toxicity and efficacy of alofanib. The study is ongoing.
- alofanib (RPT835) / Russian Pharmaceutical Technologies
A phase Ib study of alofanib, an allosteric FGFR2 inhibitor, in patients with advanced or metastatic gastric cancer. (Level 1, West Hall - Poster Board L10) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_444;
P1b
Alofanib (RPT835) is a novel selective allosteric inhibitor of FGFR2...Clinical trial information: NCT04071184. Research Funding: Skolkovo Foundation, Ruspharmtech
- | alofanib (RPT835) - R / Pharm
Enrollment open, Metastases: RPT835GC1B: Study of Alofanib in Patients With Metastatic Gastric Cancer (clinicaltrials.gov) - Sep 25, 2019
P1b, N=50, Recruiting, Sponsor: Russian Pharmaceutical Technologies
Research Funding: Skolkovo Foundation, Ruspharmtech Active, not recruiting --> Recruiting
- | alofanib (RPT835) - R / Pharm
New P1 trial, Metastases: RPT835GC1B: Study of Alofanib in Patients With Metastatic Gastric Cancer (clinicaltrials.gov) - Aug 28, 2019
P1b, N=50, Active, not recruiting, Sponsor: Russian Pharmaceutical Technologies